Cardiol Therapeutics Financials - Benzinga

Cardiol Therapeutics Inc

CRDLNASDAQ

Trade with Public

Trade with Public

$1.98

0.0351.8%

At close: Aug 31, 5:00 PM EST

$1.95

-0.025-1.27%

After Hours: 6:16 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Options Stock Report

Cardiol Therapeutics Financials

Cardiol Therapeutics (CRDL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cardiol Therapeutics Q3 EPS $(0.09), Inline

Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last

Benzinga Newsdesk

AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday

Avi Kapoor

PRO
Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate

Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from

Benzinga Newsdesk

PRO
Cardiol Therapeutics' Cash And Cash Equivalents Of $34.9M As Of December 31, 2023, Which Funds Operations Into 2026

Benzinga Newsdesk

Mid-Morning Market Update: Markets Mostly Lower; CVS Health Tops Q3 Views

Following the market opening Wednesday, the Dow traded down 0.31% to 35,939.39 while the NASDAQ fell 0.01% to 15,649.42. The S&P also fell, dropping 0.15% to 4,623.92.

Lisa Levin

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)

Shanthi Rexaline